Sino Biopharmaceutical Ltd (1177)

5.53
+0.08(+1.47%)
  • Volume:
    32,936,335
  • Bid/Ask:
    5.53/5.54
  • Day's Range:
    5.40 - 5.64

1177 Overview

Prev. Close
5.45
Day's Range
5.4-5.64
Revenue
30.99B
Open
5.49
52 wk Range
5.28-9.69
EPS
0.64
Volume
32,936,335
Market Cap
103.74B
Dividend (Yield)
0.08
(1.44%)
Average Vol. (3m)
37,753,276
P/E Ratio
8.52
Beta
0.69
1-Year Change
-22.14%
Shares Outstanding
18,759,113,730
Next Earnings Date
Mar 31, 2022
What is your sentiment on Sino Biopharmaceutical Ltd?
or
Market is currently closed. Voting is open during market hours.

Sino Biopharmaceutical Ltd Company Profile

Employees
24443
Market
Hong Kong

Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates in three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company’s principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Qingkeshu tablets, Qianping injections, Anxian capsules, Yinishu tablets, Genike capsules, Shoufu tablets, Jizhi tablets, and Leweixin injection; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, Sacubatro/Valsartan tablets, Tolvaptan tablets, Rivaroxaban tablets, Edaravone injections, Esmolol Hydrochloride injections, Esmolol Hydrochloride and Sodium Chloride injections, Polidocanol injections, Sacubitril Valsartan Sodium tablets, Urapidil Hydrochloride injections, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules, Taiyan tablets, Zoledronic Acid injections, and Yigu injections. Its principal products also comprise digestive system medicines that consists of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tianjie injections, Fengruineng injections, Tianli injections, and Tianming injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms, and Qingliming injections. In addition, the company engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, it manufactures, sells, and distributes health food; and develops medical technology. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyNeutralSellStrong SellSell
Technical IndicatorsSellStrong SellBuyStrong SellStrong Sell
SummaryNeutralSellNeutralStrong SellStrong Sell
  • M Stanley Trims CHINA CINDA TP to $1.63; Rated Equalweight
    0
    • Daiwa Axes SINO BIOPHARM TP to $11; Rated Buy
      0
      • SINO BIOPHARM Shr Once Rebounds Over 9% as Interim NP May Hike Over 5x
        0
        • SINO BIOPHARM Repurchases $28.53M Shrs; Tse Ping, Tse Hsin Splurge Over $100M to Add Stakes
          1
          • WHO agree SinoVac into EUA list at Jun 01, that Sino Biopharm have 15.3%
            0
            • Macquarie Upgrades SINO BIOPHARM to *Outperform* with $10.46 TP
              0
              • JPM Raises SINO BIOPHARM TP to $13.5; Rated ***Overweight***
                1
                • Daiwa Ramps up SINO BIOPHARM  TP to $12; Rated ***Buy***
                  0
                  • wow
                    0
                    • what is bottom this round
                      2
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.